Payment overview · 2025
General Payments
$371.32
16 reported records · 11 companies
Healthcare provider profile · identity verified
Murugesan M Siddhappan, MD
Allopathic & Osteopathic Physicians|Family Medicine · DENTON, TX · NPI 1104096437
Verified facts
What the public records show
CMS Open Payments records show Murugesan M Siddhappan, MD received $371.32 in general payments during 2025 across 16 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Xifaxan.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $98.60 | 26.6% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.99 | 18.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.34 | 10.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.85 | 8.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.18 | 6.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $20.69 | 5.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.00 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.86 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.83 | 5.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.35 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.63 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $302.33 | 15 |
| Education | $68.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $98.60 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 98 |
| Gabapentin | Gabapentin | 312 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 75 |
| Potassium Chloride | Potassium Chloride | 267 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 44 |
| Furosemide | Furosemide | 247 | 68 |
| Lisinopril | Lisinopril | 238 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 57 |
| Metformin Hcl | Metformin Hcl | 183 | 48 |
| Methylprednisolone | Methylprednisolone | 178 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 53 |
| Eliquis | Apixaban | 162 | 20 |
| Omeprazole | Omeprazole | 161 | 47 |
| Trazodone Hcl | Trazodone Hcl | 160 | 44 |
| Montelukast Sodium | Montelukast Sodium | 159 | 40 |
| Azithromycin | Azithromycin | 128 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 34 |
| Losartan Potassium | Losartan Potassium | 118 | 26 |
| Tramadol Hcl | Tramadol Hcl | 118 | 32 |
| Levofloxacin | Levofloxacin | 117 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 30 |
| Meloxicam | Meloxicam | 110 | 26 |
| Ozempic | Semaglutide | 110 | 18 |
| Simvastatin | Simvastatin | 110 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 102 | 32 |
| Alendronate Sodium | Alendronate Sodium | 96 | 28 |
| Carvedilol | Carvedilol | 95 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 89 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 22 |
| Allopurinol | Allopurinol | 85 | 19 |
| Clonazepam | Clonazepam | 80 | 13 |
| Jardiance | Empagliflozin | 80 | 21 |
| Ibuprofen | Ibuprofen | 78 | 19 |
| Clonidine Hcl | Clonidine Hcl | 77 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 19 |
| Lorazepam | Lorazepam | 74 | 17 |
| Finasteride | Finasteride | 72 | 22 |
| Pregabalin | Pregabalin | 71 | 14 |
| Sertraline Hcl | Sertraline Hcl | 71 | 15 |
| Latanoprost | Latanoprost | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 17 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Diazepam | Diazepam | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Folic Acid | Folic Acid | 52 | 15 |
| Prednisone | Prednisone | 50 | 18 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 42 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | 12 |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Metronidazole | Metronidazole | 34 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 25 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Fluconazole | Fluconazole | 24 | 14 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Torsemide | Torsemide | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $371.32 · 16 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, INCEPTIV, Korlym, MOUNJARO, Ozempic, PAXLOVID, Rybelsus, TONMYA, The Cologuard Plus Collection Kit, VYEPTI, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error